Cargando…

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel Azim, Hamdy, Kassem, Loay, Shohdy, Kyrillus Samaan, Eshaak, Boules, Anis, Shady Elia, Kamal, Nermine Shawky
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438837/ https://www.ncbi.nlm.nih.gov/pubmed/30941241 http://dx.doi.org/10.4048/jbc.2019.22.e2

Ejemplares similares

Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
por: Kassem, Loay, et al.
Publicado: (2019)

The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
por: Azim, Hamdy A., et al.
Publicado: (2023)

Prognostic Impact of Cytotoxic CD4 T Cells in Tumor Immune Microenvironment of Patients with Breast Cancer
por: Shohdy, Kyrillus S., et al.
Publicado: (2021)

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer()
por: Azim, Hamdy A., et al.
Publicado: (2016)

Availability of Informal Caregivers for Palliative Care Patients with Cancer: Is there a Difference between Higher- and Lower-Income Settings
por: Abdel-Malek, Raafat, et al.
Publicado: (2019)

Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine
por: Shohdy, Kyrillus S, et al.
Publicado: (2018)

Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis
por: Owen, Kathryn, et al.
Publicado: (2022)

Both Castration and Goserelin Acetate Ameliorate Myocardial Ischemia Reperfusion Injury and Apoptosis in Male Rats
por: Hadi, Najah R., et al.
Publicado: (2014)

Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experience
por: Shohdy, Kyrillus S., et al.
Publicado: (2021)

Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial
por: Abo El-Enen, Mohamed, et al.
Publicado: (2016)

Update on the management of prostate cancer with goserelin acetate: patient perspectives
por: Wilson, Shandra
Publicado: (2009)

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
por: Gupta, Aanchal, et al.
Publicado: (2021)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature
por: Mahadevan, Aditya, et al.
Publicado: (2023)

Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer
por: Jiang, Hang, et al.
Publicado: (2014)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Primary Mediastinal Choriocarcinoma in an Elderly Patient with Concurrent Goserelin-Treated Prostate Adenocarcinoma
por: Røge, Rasmus, et al.
Publicado: (2019)

Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
por: Aljabri, Belal, et al.
Publicado: (2021)

No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro
por: Hermann, Robert M, et al.
Publicado: (2007)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: A case report and review of the literature
por: Yang, Jia-Wen, et al.
Publicado: (2021)

Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats
por: Yutong, Mao, et al.
Publicado: (2023)

Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis
por: Azim, Hamdy A., et al.
Publicado: (2023)

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
por: Cheng, Tsui Fen, et al.
Publicado: (2012)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial
por: R, Leonard, et al.
Publicado: (2020)

Identification of predictors based on drug targets highlights accurate treatment of goserelin in breast and prostate cancer
por: Zhao, Yue, et al.
Publicado: (2021)

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
por: Shohdy, Kyrillus S., et al.
Publicado: (2023)

The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
por: Azim, Hamdy A, et al.
Publicado: (2018)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)

Lateral Quadratus Lumborum Block versus Transversus Abdominis Plane Block in Laparoscopic Surgery: A Randomized Controlled Study
por: Fargaly, Omar Sayed, et al.
Publicado: (2022)

Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016
por: Elmehrath, Ahmed O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_813im4k5icv0q0000p9nb771ps